Clinical Trials Logo

Neoplasms by Histologic Type clinical trials

View clinical trials related to Neoplasms by Histologic Type.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05160168 Terminated - Neoplasms Clinical Trials

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Start date: January 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).

NCT ID: NCT05153408 Terminated - Neoplasms Clinical Trials

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Start date: January 13, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.

NCT ID: NCT03495921 Terminated - Neoplasms Clinical Trials

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

VITA
Start date: August 21, 2018
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide compared to the standard treatment of irinotecan and temozolomide alone. The main question it aimed to answer is "Will participants who receive Vigil in addition to irinotecan and temozolomide have a prolonged time to progression and improved quality of life compared to the participants who receive irinotecan and temozolomide alone?".

NCT ID: NCT02543645 Terminated - Clinical trials for Non-small Cell Lung Cancer

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Start date: October 2015
Phase: Phase 1
Study type: Interventional

This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).* *Note: This Study was terminated prior to initiation of Phase II

NCT ID: NCT02386111 Terminated - Neoplasms Clinical Trials

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Start date: May 2015
Phase: Phase 1
Study type: Interventional

This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and sunitinib. The study will enroll patients with metastatic clear cell renal cell carcinoma.

NCT ID: NCT01234480 Terminated - Neoplasms Clinical Trials

Intended Use Study of the BD SurePath Plus™ Pap

Start date: September 2010
Phase:
Study type: Interventional

This study will provide data on the performance of the BD SurePath Plus™ Pap test for identifying high grade cervical disease. This study will be conducted with approximately 12,500 women undergoing routine cervical cancer screening, of whom women with abnormal cytology and/or positive HPV test will be selected to undergo colposcopy and biopsy/ECC. Subjects with abnormal cytology results with biopsy results of less than or equal to CIN1 or CIN2 untreated will be asked to return in 6-8 months for follow-up testing. Subjects may be asked to proceed to a longer-term follow-up study and undergo cytological evaluation annually for 3 years (separate study).

NCT ID: NCT01009593 Terminated - Neoplasms Clinical Trials

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Start date: January 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.